stockrow
Friday 6 November 2026
Export NXGL’s income statement to Excel — free account
NexGel, Inc.
NXGL Healthcare Medical Instruments & Supplies
NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024.
- Revenue
- +27.8%
- EPS
- −344.4%
- Free cash flow
- −432.3%
- Total debt
- +353.8%
Quarter to June 2026, against a year earlier
3.60
0.52
−12.62%
Follow NXGL
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
1 | 4 | 5 | 6 |
+8 more TTM periods Free account |
| (117.57%) | (63.98%) | (54.69%) | (54.54%) | ||
| (34.21%) | (29.18%) | (27.98%) | (25.96%) | ||
ROIC |
(45.29%) | (50.63%) | (45.90%) | (41.45%) | |
Return on Tangible Assets |
97.23% | (76.28%) | (89.90%) | (67.13%) | |
Average Days of Receivables |
32.64 | 21.45 | 21.51 | 26.25 | |
Free Cash Flow per Share |
(7.41) | (3.64) | (3.69) | (6.42) | |
Free Cash Flow |
(3.34) | (1.49) | (1.45) | (2.56) | |
Capital Expenditures |
(0.13) | (0.08) | (0.14) | (0.11) | |
| Other line items | |||||
Cash ROIC |
(30.72%) | (17.34%) | (21.68%) | (31.20%) | |
Accounts Receivable Turnover |
13.17 | 14.19 | 14.22 | 13.46 | |
Accounts Payable Turnover |
3.02 | 4.19 | 5.36 | 5.03 | |
Inventory Turnover |
3.80 | 3.35 | 3.58 | 3.60 | |
Average Days of Payables |
182.59 | 95.77 | 68.07 | 64.92 | |
Days of Inventory on Hand |
107.30 | 120.01 | 111.48 | 107.79 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.17% | 0.00% | 0.02% | 0.07% | |
Selling, General and Administrative Expense of Revenue |
79.67% | 70.25% | 68.81% | 66.86% | |
Share Based Compensation of Revenue |
5.16% | 5.60% | 5.73% | 5.09% | |
Interest Coverage |
— | (46.49) | (60.95) | (46.55) | |
Operating CF/Net income |
0.52 | 0.44 | 0.44 | 0.85 | |
Depreciation/Fixed assets |
1.82 | 0.40 | 0.38 | 0.34 | |
Capex/Depreciation |
(0.04) | (0.10) | (0.19) | (0.16) | |
Revenue per Share |
26.77 | 27.46 | 29.08 | 29.27 | |
Operating CF per Share |
(7.11) | (3.45) | (3.34) | (6.15) | |
Capex per Share |
(0.30) | (0.19) | (0.35) | (0.28) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 2 Nov 2026